Press Release
Stay updated with our latest news and media
Daewoong Launches Dyslipidemia Treatment in Surabaya, Indonesia… “Advancing Cardiovascular Health in East Java”
Writer
Manager
February 1, 2026
- Following its Jakarta launch, Daewoong’s Surabaya launch expands optimal treatment solutions for high-risk patients in East Java
- Focus on Indonesia’s 11.7% diabetes prevalence—higher than the global average—to establish a precise management environment for metabolic diseases
- “Patients with diabetes are at high cardiovascular risk… Early combination therapy is key” said Dr. Soebagijo Adi Soelistijo

Surabaya – February 1st, 2026

Daewoong Pharmaceutical Indonesia (hereafter “Daewoong”) has officially launched its fixed-dose combination therapy for dyslipidemia in Surabaya, Indonesia’s second-largest city, following its initial introduction in Jakarta. This launch is significant as it expands specialized treatment solutions in East Java, where the prevalence of diabetes is notably high.

On February 1, Daewoong hosted the ‘Dyslipidemia Treatment Surabaya Regional Launch Symposium’ at Novotel Surabaya for approximately 100 local medical professionals. The event highlighted optimized LDL-C (low-density lipoprotein cholesterol) management strategies and shared the latest clinical insights on the dual-mechanism combination of Ezetimibe and Rosuvastatin.

dr. Jeffrey Daniel Adipranoto, Sp.JP(K), FIHA, FESC, FSCAI, a cardiology specialist at RSUD Dr. Soetomo, participated as a speaker at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.

Risk of cardiometabolic disease rises with diabetes…‘Early combination therapy’ for dyslipidemia discussed in East Java

The symposium featured in-depth discussions regarding high risk factors for cardiovascular metabolic diseases in East Java. According to the ‘Indonesia Health Survey (SKI 2023)’ by the Ministry of Health, Indonesia’s diabetes prevalence stands at 11.7%, exceeding the global average of 10.6%. East Java, in particular, is a key region with a large population of diabetes patients and high population density.

Dr. Soebagijo Adi Soelistijo, an endocrinologist at Dr. Soetomo Regional Public Hospital, emphasized, “When accompanied by diabetes, the risk of cardiovascular metabolic disease increases sharply, necessitating stricter cholesterol management”. He highlighted that “since statin monotherapy often has limitations in achieving LDL-C targets for diabetic patients, early combination therapy—which simultaneously inhibits both cholesterol synthesis and absorption to provide a powerful lowering effect—is an essential strategy”.

Dr. dr. Soebagijo Adi Soeslistijo, Sp.PD-KEMD, FINASIM, FACP, an endocrinologist at RSUD Dr. Soetomo, emphasized that when accompanied by diabetes, the risk of cardiometabolic disease increases significantly, thereby necessitating stricter cholesterol management. This was highlighted at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.

In addition, Dr. dr. Suryono, Chairman of the Indonesian Heart Association (PERKI) Surabaya, remarked, “In real-world clinical settings, treatment is often insufficient or inadequately controlled”. He evaluated that “Daewoong’s low-dose combination-based dyslipidemia treatment will play a crucial role in addressing complex cardiovascular metabolic disease challenges”.

Dr. dr. Suryono, Sp.JP(K), FIHA, Chair of the Indonesian Society of Cardiology (PERKI) Surabaya, stated that in daily clinical practice, treatment is often suboptimal or not well controlled. This was presented at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.

Maximizing Treatment Efficiency with A Powerful Dual Mechanism… Superior LDL-C Lowering Effect Compared to Monotherapy

Daewoong’s treatment maximizes efficiency through the combined action of Rosuvastatin (inhibiting cholesterol synthesis in the liver) and Ezetimibe (inhibiting cholesterol absorption in the small intestine). A key feature is the ability to achieve a safer yet more powerful lowering effect even with relatively low doses.

Dr. dr. Budi Baktijasa Dharmadjati, Sp.JP(K), FIHA, a cardiology specialist at RSUD Dr. Soetomo, participated as a speaker at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.

Prof. Yudi Her Oktaviono, Head of Cardiology and Vascular Medicine at Dr. Soetomo Regional Public Hospital, stated, “Approximately 91.5% of coronary artery disease patients in Indonesia fail to reach the very-high-risk target of 55 mg/dL”. He added, “In this context, early combination therapy with proven efficacy is a rational strategy to bridge the treatment gap and dramatically improve patient prognosis”.

Prof. Dr. dr. Yudi Her Oktaviono, Sp.JP(K), M.M., FIHA, FICA, FASCC, FSCAI, Head of the Division of Cardiology and Vascular Medicine at RSUD Dr. Soetomo, explained that approximately 91.5% of patients with coronary artery disease in Indonesia have not yet achieved the LDL-C target for the very high-risk category, namely 55 mg/dL. This was conveyed during the scientific lecture titled “Control LDL, Prevent Heart Disease” at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.

Establishing a Precise Prescribing Environment with Indonesia’s First ‘3-Dose Lineup Including Low-Dose’

Daewoong has established a comprehensive lineup of three dosage strengths (10/5 mg, 10/10 mg, and 10/20 mg), including Indonesia’s first 10/5 mg low-dose option. This allows for precise, personalized prescriptions based on an individual patient’s cardiovascular risk level. By offering a single-pill combination, it is expected to significantly improve convenience and treatment outcomes for patients with low medication adherence.

From left to right: Prof. Dr. dr. Yudi Her Oktaviono, Sp.JP(K), M.M., FIHA, FICA, FASCC, FSCAI; Dr. dr. Budi Baktijasa Dharmadjati, Sp.JP(K), FIHA; Dr. dr. Soebagijo Adi Soeslistijo, Sp.PD-KEMD, FINASIM, FACP; and dr. Jeffrey Daniel Adipranoto, Sp.JP(K), FIHA, FESC, FSCAI, posed for a group photo at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.

Baik In Hyun, Executive Director of Indonesia Business Division at Daewoong stated, “It is meaningful to introduce scientifically proven treatment options to medical professionals in East Java”. He concluded, “We will continue to strengthen cooperation with local medical societies to fulfill our responsibility as a healthcare partner dedicated to preventing cardiovascular disease and improving the quality of life for the Indonesian people”.

Baik In Hyun, Director of Daewoong Pharmaceutical Indonesia, stated that the launch marks a meaningful step in introducing evidence-based therapeutic options to healthcare professionals in East Java, at the “Dyslipidemia Treatment Surabaya Regional Launch Symposium”, held in Surabaya on February 1, 2026.
recent post
Forward
Press Release
Daewoong Launches Dyslipidemia Treatment in Surabaya, Indonesia… “Advancing Cardiovascular Health in East Java”
Press Release
Daewoong Advances GERD Treatment Innovation in Indonesia through Fexuprazan IIT Study